DPP4 and hepatocellular carcinoma: The network meta‐analysis revealed a clear hierarchy of HCC prevention efficacy across antidiabetic drug classes, with GLP‐1RAs ranking highest (SUCRA 0.89), followed by SGLT‐2 inhibitors and DPP‐4 inhibitors.